In last trading session, Aldeyra Therapeutics Inc (NASDAQ:ALDX) saw 1.1 million shares changing hands with its beta currently measuring 0.67. Company’s recent per share price level of $2.17 trading at $0.09 or 4.33% at ring of the bell on the day assigns it a market valuation of $129.97M. That closing price of ALDX’s stock is at a discount of -231.8% from its 52-week high price of $7.20 and is indicating a premium of 47.47% from its 52-week low price of $1.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.69 million shares which gives us an average trading volume of 1.80 million if we extend that period to 3-months.
For Aldeyra Therapeutics Inc (ALDX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Upright in the green during last session for gaining 4.33%, in the last five days ALDX remained trading in the green while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $2.17 price level, adding 6.06% to its value on the day. Aldeyra Therapeutics Inc’s shares saw a change of -56.51% in year-to-date performance and have moved 7.96% in past 5-day. Aldeyra Therapeutics Inc (NASDAQ:ALDX) showed a performance of 2.36% in past 30-days. Number of shares sold short was 4.95 million shares which calculate 1.49 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 11 to the stock, which implies a rise of 80.27% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would drop -360.83% in reaching the projected high whereas dropping to the targeted low would mean a loss of -360.83% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 15.99% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -8.30% while estimates for its earnings growth in next 5 years are of 37.68%.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Insiders are in possession of 3.13% of company’s total shares while institution are holding 55.87 percent of that, with stock having share float percentage of 57.67%. Investors also watch the number of corporate investors in a company very closely, which is 55.87% institutions for Aldeyra Therapeutics Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at ALDX for having 9.28 million shares of worth $30.7 million. And as of 2024-06-30, it was holding 15.6121 of the company’s outstanding shares.
The second largest institutional holder is KNOLL CAPITAL MANAGEMENT, LLC, which was holding about 5.48 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2158 of outstanding shares, having a total worth of $18.12 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.76 shares of worth $3.82 million or 2.94% of the total outstanding shares. The later fund manager was in possession of 1.32 shares on Mar 31, 2025 , making its stake of worth around $2.87 million in the company or a holder of 2.21% of company’s stock.
